Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Alphatec Holdings, Inc. $ATEC

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 175,423 shares of the medical technology company’s stock, valued at approximately $3,691,000.

A number of other hedge funds have also made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Alphatec by 15.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,131 shares of the medical technology company’s stock valued at $907,000 after acquiring an additional 5,923 shares during the period. Merit Financial Group LLC purchased a new position in shares of Alphatec in the 4th quarter valued at $207,000. Third View Private Wealth LLC purchased a new position in shares of Alphatec in the 4th quarter valued at $335,000. Aberdeen Group plc increased its stake in Alphatec by 29.7% during the 4th quarter. Aberdeen Group plc now owns 1,286,195 shares of the medical technology company’s stock worth $27,062,000 after buying an additional 294,792 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Alphatec by 30.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 978,343 shares of the medical technology company’s stock worth $20,584,000 after buying an additional 227,914 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Insider Buying and Selling at Alphatec

In other news, General Counsel Tyson Eliot Marshall sold 88,835 shares of Alphatec stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $12.49, for a total value of $1,109,549.15. Following the completion of the transaction, the general counsel directly owned 559,459 shares of the company’s stock, valued at approximately $6,987,642.91. The trade was a 13.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Scott Lish sold 260,535 shares of Alphatec stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $12.30, for a total transaction of $3,204,580.50. Following the completion of the transaction, the chief operating officer directly owned 815,704 shares of the company’s stock, valued at $10,033,159.20. This trade represents a 24.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 726,972 shares of company stock valued at $9,184,386. Corporate insiders own 22.80% of the company’s stock.

Alphatec Price Performance

ATEC opened at $9.30 on Thursday. The company has a 50-day moving average of $11.86 and a 200-day moving average of $15.99. The company has a market capitalization of $1.41 billion, a P/E ratio of -9.79 and a beta of 1.12. Alphatec Holdings, Inc. has a 1-year low of $9.15 and a 1-year high of $23.29. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to analyst estimates of $212.67 million. During the same period last year, the firm posted ($0.23) earnings per share. The company’s quarterly revenue was up 20.4% on a year-over-year basis. Equities analysts expect that Alphatec Holdings, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Ratings Changes

ATEC has been the topic of several analyst reports. Barclays lifted their price target on shares of Alphatec from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Friday, March 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Alphatec in a research note on Wednesday, February 25th. Lake Street Capital reaffirmed a “buy” rating on shares of Alphatec in a research note on Wednesday, February 25th. Finally, Stifel Nicolaus dropped their price target on shares of Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.82.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.